<SEC-DOCUMENT>0000914475-21-000004.txt : 20210108
<SEC-HEADER>0000914475-21-000004.hdr.sgml : 20210108
<ACCEPTANCE-DATETIME>20210108073216
ACCESSION NUMBER:		0000914475-21-000004
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210108
DATE AS OF CHANGE:		20210108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		21515656

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20210108.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:437b6fa0-e28d-4316-b851-196683fa9ff4,g:e624b653-28b5-41e7-b4c6-2ceb24602179,d:0f24ffc3cc224cb3b99b3543f3f59405--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20210108</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV80L2ZyYWc6MWNmM2Y4M2U1NDk2NGFkZThhMWY0MTgyNGZlNTUzNWYvdGFibGU6OTAxN2I3YzExZmJiNDZkMDlkYmU0NjlkNTJkZDMzZDYvdGFibGVyYW5nZTo5MDE3YjdjMTFmYmI0NmQwOWRiZTQ2OWQ1MmRkMzNkNl8wLTEtMS0xLTA_9fb942c2-9326-466e-b4d9-2306031e0875">false</ix:nonNumeric><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV80L2ZyYWc6MWNmM2Y4M2U1NDk2NGFkZThhMWY0MTgyNGZlNTUzNWYvdGFibGU6OTAxN2I3YzExZmJiNDZkMDlkYmU0NjlkNTJkZDMzZDYvdGFibGVyYW5nZTo5MDE3YjdjMTFmYmI0NmQwOWRiZTQ2OWQ1MmRkMzNkNl8xLTEtMS0xLTA_ff34529b-a185-400f-b87e-d6d10d7786c0">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20210108.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0f24ffc3cc224cb3b99b3543f3f59405_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYw_94033921-3e0c-4430-a25f-cabf084dc33c">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8yMjI_6fd0cc14-be06-49e3-9a4c-7919779a866d">January&#160;8, 2021</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYx_80af7910-82bd-4e29-82a5-59baa262ba44">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN18wLTAtMS0xLTA_6459ebdb-4c25-487d-859e-c1ac9d86fd14">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN18wLTEtMS0xLTA_f12442d2-6a8f-4c4d-98ab-9c36089c63fd">0-22705</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN18wLTItMS0xLTA_c5fabeb5-52c8-46ae-8cc8-b3b22f1e21cb">33-0525145</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(State or Other Jurisdiction</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Commission</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(IRS Employer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:63.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN180LTAtMS0xLTA_a4d1ac41-5b87-4569-b24e-658a60935bd7">12780 El Camino Real,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:62.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN181LTAtMS0xLTA_3956a238-ad0c-4c8f-a7ff-dad9954e4d6d">San Diego,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN181LTEtMS0xLTA_2d49e314-b275-410b-9356-e47102f28627">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN181LTItMS0xLTA_2c6949c1-4fe6-4690-bfc9-a5c6e68c756f">92130</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:62.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:64.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY0_1875815b-a9b4-4ff0-a864-63baba289a97">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYy_140dae5b-d9e9-474a-949c-26e46232c08b">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6NmFjOTc3ZjA4YTc0NDQyYWEwM2JhNTExYjg5NDE0OWUvdGFibGVyYW5nZTo2YWM5NzdmMDhhNzQ0NDJhYTAzYmE1MTFiODk0MTQ5ZV8yLTAtMS0xLTA_7569f06b-ba07-4e60-9d5f-e0738760f31a">Common Stock, $0.001 par value</ix:nonNumeric></span></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6NmFjOTc3ZjA4YTc0NDQyYWEwM2JhNTExYjg5NDE0OWUvdGFibGVyYW5nZTo2YWM5NzdmMDhhNzQ0NDJhYTAzYmE1MTFiODk0MTQ5ZV8yLTItMS0xLTA_f39fe4ec-240e-49d9-a514-ea902b9af98c">NBIX</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6NmFjOTc3ZjA4YTc0NDQyYWEwM2JhNTExYjg5NDE0OWUvdGFibGVyYW5nZTo2YWM5NzdmMDhhNzQ0NDJhYTAzYmE1MTFiODk0MTQ5ZV8yLTQtMS0xLTA_56735f14-f29a-4866-8177-177b21c0df2c">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY1_ac6ec27a-51bb-478e-91ba-c4b97bfe95c6">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY2_b3ca8f22-6e79-4736-a6ce-b98d1df7dae8">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYz_6c6b8dde-5077-47cb-8005-7161a23be514">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY3_3d3eb375-7c54-4324-b76f-80f65f2240ce">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY4_cb272ef5-4d86-4f3a-9717-5be75e86c199">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0f24ffc3cc224cb3b99b3543f3f59405_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;), issued a press release announcing preliminary fourth quarter 2020 and full year 2020 net product sales results. The Company&#8217;s financial statements for the fourth quarter 2020 and full year 2020 have not yet been completed and could result in changes to these preliminary net product sales results. The press release also contained certain 2021 expected milestones related to the Company&#8217;s products and product candidates. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent the Company&#8217;s estimates and assumptions only as of the date of this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20210108exhibit991.htm">Press Release dated January 8, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0f24ffc3cc224cb3b99b3543f3f59405_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: January&#160;8, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix-20210108exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icc6bec8646c644878dcdf6f7f7266c80_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 <br>Net Product Sales Results and 2021 Program Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">s</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million, Respectively</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) Preliminary Full-Year 2020 Net Product Sales and TRx Both Grew 32% to Approximately $993 Million and 175,700 TRx Respectively Versus the Prior Year</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company Plans to Provide Clinical Data for Key Programs and Expects to Initiate Seven Additional Mid-to-Late Stage Clinical Studies in 2021 for Neurological, Endocrine and Psychiatric Disorders</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SAN DIEGO, Jan. 8, 2021 - Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (valbenazine) for 2020, and key commercial and clinical development milestones for 2021. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Annual J.P. Morgan Healthcare Conference to be held virtually on Monday, January 11 at 2&#58;00 p.m. Eastern Time, followed by a Question and Answer session at approximately 2&#58;20 p.m. Eastern Time. </font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preliminary Fourth Quarter and Full-Year 2020 INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (valbenazine) Net Product Sales and Inventory Adjusted Net Product Sales (Unaudited)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based on preliminary unaudited financial information, the Company expects INGREZZA net product sales for the three months and full-year ended December 31, 2020 to be approximately $240 million and $993 million respectively. Preliminary analysis of INGREZZA net product sales suggests&#58;</font></div><div style="margin-bottom:3pt;padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.5pt">INGREZZA inventory adjusted net product sales for the fourth quarter were approximately $258 million reflecting an $18 million channel inventory decrease in Q4 </font></div><div style="margin-bottom:3pt;padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.5pt">New prescriptions and refills increased in the fourth quarter of 2020 vs. the third quarter of 2020</font></div><div style="margin-bottom:6pt;padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.5pt">Full-year 2020 total INGREZZA prescriptions grew 32% to approximately 175,700 versus 2019 total prescriptions of approximately 132,700 </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;I am very proud of our team&#8217;s resilience and adaptability to bring INGREZZA to patients living with tardive dyskinesia this past year and we remain encouraged by the continued strength in persistence and refill rates, which is a testament to the many benefits of INGREZZA. We also continue to focus on healthcare provider educational initiatives, patient outreach programs and investing in telemedicine capabilities to improve diagnosis and treatment rates for the estimated 80% of patients with tardive dyskinesia who have not yet been diagnosed,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. &#8220;Adding to our movement disorder portfolio, we launched our second commercial treatment, ONGENTYS, and continue to make great progress in our development programs with plans to initiate seven mid-to-late stage clinical studies in 2021 focused on neurological, endocrine and psychiatric disorders.&#8221;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2021 Expected Milestones and Key Activities</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Program</font></div></td><td colspan="3" style="background-color:#0070c0;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indication</font></div></td><td colspan="3" style="background-color:#0070c0;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2021 Milestones &#47; Key Activities</font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Valbenazine</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chorea in Huntington Disease</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Phase III Top-Line Data Expected in Q4 2021</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Neurological Indication</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase III</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Psychiatric Indication</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase II</font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Crinecerfont</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Congenital Adrenal Hyperplasia (Adult)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Continue Phase III Enrollment</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Congenital Adrenal Hyperplasia (Pediatric)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase III</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NBI-1065844</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Negative Symptoms of Schizophrenia</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Phase II Top-Line Data Expected in</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1st Half of 2021</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NBI-1065845</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Treatment Resistant Depression</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase II</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NBI-1065846</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Anhedonia in Depression</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase II</font></div></td></tr><tr style="height:39pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NBI-827104</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rare Pediatric Epilepsy&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Epileptic Encephalopathy with Continuous Spike and Wave During Sleep</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Continue Phase II Enrollment</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Neurological Indication</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase II</font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NBI-921352</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Focal Onset Seizure in Adults</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Initiate Phase II</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rare Pediatric Epilepsy&#58; SCN8A-DEE</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ongoing Dialogue with FDA</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NBIb-1817</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Gene Therapy for Parkinson's Disease</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Determine Regulatory Path with FDA</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Tardive Dyskinesia (TD)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and&#47;or other body parts, which may be disruptive and negatively impact patients. The condition is caused by prolonged use of treatments that block dopamine receptors in the brain, such as antipsychotics commonly prescribed to treat mental illnesses such as schizophrenia, bipolar disorder and depression, and certain anti-nausea medications. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect at least 500,000 people in the U.S.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (valbenazine) Capsules</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first FDA-approved product indicated for the treatment of adults with tardive dyskinesia, a condition associated with uncontrollable, abnormal and repetitive movements of the face, torso and&#47;or other body parts.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INGREZZA is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with tardive dyskinesia. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed in Neurocrine Biosciences&#8217;s laboratories, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Important Information</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approved Use</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is not known if INGREZZA is safe and effective in children.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Important Safety Information</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Do not take INGREZZA if you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are allergic to valbenazine, or any of the ingredients in INGREZZA.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INGREZZA may cause serious side effects, including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Sleepiness (somnolence).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Do not drive, operate heavy machinery, or do other dangerous activities until you know how INGREZZA affects you.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Heart rhythm problems (QT prolongation).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> INGREZZA may cause a heart problem known as QT prolongation.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Symptoms of QT prolongation may include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; fast, slow, or irregular heartbeat, shortness of breath, dizziness or fainting.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Parkinson-like symptoms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Symptoms include&#58; shaking, body stiffness, trouble moving or walking, or keeping your balance.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Before taking INGREZZA, tell your healthcare provider about all of your medical conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">including if you&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tell your healthcare provider about all the medicines you take,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> including prescription and over-the-counter medicines, vitamins and herbal supplements.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The most common side effect of INGREZZA is sleepiness (somnolence). Other side effects include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> changes in balance (balance problems, dizziness) or an increased risk of falls, headache, feelings of restlessness, dry mouth, constipation, and blurred vision.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These are not all of the possible side effects of INGREZZA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please see INGREZZA full </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">About Neurocrine Biosciences</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie)</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to&#58; our preliminary unaudited financial information&#59; the benefits to be derived from our products and product candidates&#59; the value our products and&#47;or our product candidates may bring to patients&#59; the continued success of INGREZZA&#59; our financial and operating performance, our collaborative partnerships&#59; expectations regarding the impact of COVID-19 on our business, including patient and healthcare provider access to INGREZZA, our ability to continue our ongoing clinical trials and other development activities, and to otherwise advance our business objectives&#59; and the timing of completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are&#58; risks and uncertainties associated with items that may be identified during the financial statement closing process that cause adjustments to the estimates included in this press release&#59; our future financial and operating performance&#59; risks associated with the commercialization of INGREZZA and ONGENTYS&#59; the impact of the COVID-19 pandemic on our business and the business operations of our customers&#59; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions&#59; risk and uncertainties related to any COVID-19 quarantines, shelter-in-place, social distancing and other government orders that are currently in place or that may be put in place in the future, including the impact of such orders on our business operations and the business operations of the third parties on which we rely&#59; risks related to the development of our product candidates&#59; risks associated with our dependence on third parties for development and manufacturing activities related to INGREZZA and our product candidates, and our ability to manage these third parties&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates&#59; risks associated with our dependence on AbbVie for the commercialization of ORILISSA and ORIAHNN, as well as the continued development of elagolix&#59; risks associated with our dependence on BIAL for manufacturing activities for ONGENTYS, and our ability to manage BIAL&#59; risks that clinical development activities may not be completed on time or at all, or may be delayed for regulatory, manufacturing, COVID-19 or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; risks that the potential benefits of the agreements with our collaboration partners may never be realized&#59; risks that our products, and&#47;or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; and other risks described in our periodic reports filed with the SEC, including without limitation our quarterly report on Form 10-Q for the quarter ended September 30, 2020. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">This press release refers to preliminary unaudited net sales in certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the comparable GAAP financial measures, which are included in this press release. </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">###</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Contact&#58; Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Navjot Rai (Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7623</font></div><div style="margin-bottom:6pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;neurocrine.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Todd Tushla (Investors)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7143</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;neurocrine.com</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20210108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:437b6fa0-e28d-4316-b851-196683fa9ff4,g:e624b653-28b5-41e7-b4c6-2ceb24602179-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20210108" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20210108">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210108_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210108_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20210108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>nbix-20210108_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:437b6fa0-e28d-4316-b851-196683fa9ff4,g:e624b653-28b5-41e7-b4c6-2ceb24602179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20210108.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>nbix-20210108_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:437b6fa0-e28d-4316-b851-196683fa9ff4,g:e624b653-28b5-41e7-b4c6-2ceb24602179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20210108.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended" id="i1da464df0196417c81ea97b1f713cd16_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nbix-20210108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:437b6fa0-e28d-4316-b851-196683fa9ff4,g:e624b653-28b5-41e7-b4c6-2ceb24602179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_ee52d5c1-4fc7-445a-b838-2f5a3af8277f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5d8ec569-9ad1-4906-85f9-c701196380ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_78ebcbe9-d83a-4d26-81ef-47dae973b5d7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2e1a30ac-5cb9-4342-8d05-0eed309f9905_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4acf34dd-b04b-4f2a-b1f7-4df739e442c6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6a508138-9234-427b-a6e9-3e83429a3ade_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f09a8964-d259-46b1-86ea-9f6d7d8b3a55_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1c0bcdef-dc63-4e50-bf5f-d22fa8596776_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2f460fc0-f3d8-44e0-8b3b-80bb70fa0f94_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_3b1b03ef-aa95-4724-9d02-5201d1786b2e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0f95efc8-a0b2-4158-8718-f708a8581e65_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_87fb1966-7608-488a-b342-8289b462a561_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8de49755-33b9-4044-9939-ae2a9e95c0b3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_13bb7d2c-8059-429c-acb8-6d039a9d5430_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f3628aa1-869a-43a8-a667-f62087e10dd6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ddf3e32b-fd28-4b90-8817-a6eac0a9c7ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_729a0dad-0101-46fa-9688-f9bcbdf09cfd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7773d1fe-7211-4f96-bfe2-4cd67ea17667_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_00abac70-78ea-4b56-bd5e-f09c22359da5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_65243282-608d-4d70-8632-19a19216a8c3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3e8605fe-532a-4c7b-804d-84f1b3e64e99_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4fc02eeb-2e2e-417f-91c1-13927e8340eb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nbix-20210108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:437b6fa0-e28d-4316-b851-196683fa9ff4,g:e624b653-28b5-41e7-b4c6-2ceb24602179-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20210108.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_26ae8599-12e1-4ee9-8379-47181d326b05" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_DocumentType_26ae8599-12e1-4ee9-8379-47181d326b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_874ebbed-42b5-4236-9cdf-0dd237fe9d1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_DocumentPeriodEndDate_874ebbed-42b5-4236-9cdf-0dd237fe9d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_27635dfd-8dc0-4b3a-9d9f-35e7433d08d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityRegistrantName_27635dfd-8dc0-4b3a-9d9f-35e7433d08d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f6749981-1fcb-4aa1-888e-a25117f1761f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f6749981-1fcb-4aa1-888e-a25117f1761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_237dd11c-4c29-4d16-9e16-a4d2bee4ecc4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityFileNumber_237dd11c-4c29-4d16-9e16-a4d2bee4ecc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_165d9f27-cd5d-4b1c-9104-2f650002cda4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityTaxIdentificationNumber_165d9f27-cd5d-4b1c-9104-2f650002cda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ea903bb2-fdc3-48b7-a6ed-46f4c9a93333" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityAddressAddressLine1_ea903bb2-fdc3-48b7-a6ed-46f4c9a93333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_30acf05f-dba1-4227-810e-785d02faaf6f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityAddressCityOrTown_30acf05f-dba1-4227-810e-785d02faaf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_040501c3-ef1c-4afe-847c-791404cbbffe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityAddressStateOrProvince_040501c3-ef1c-4afe-847c-791404cbbffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f7f97fbf-a962-426e-9fd4-479ba59dced4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityAddressPostalZipCode_f7f97fbf-a962-426e-9fd4-479ba59dced4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3fffd2fd-bbe2-44f1-ad9a-720777473963" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_CityAreaCode_3fffd2fd-bbe2-44f1-ad9a-720777473963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a16d8e95-864e-4a17-be42-c43f011ab00b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_LocalPhoneNumber_a16d8e95-864e-4a17-be42-c43f011ab00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ca4842db-9682-4f6a-a669-dcba4676e752" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_Security12bTitle_ca4842db-9682-4f6a-a669-dcba4676e752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ac554ff4-b0ea-47e8-a361-18306603f25d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_TradingSymbol_ac554ff4-b0ea-47e8-a361-18306603f25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7b927cbf-504f-4ed1-b0ee-3b8538a56215" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_SecurityExchangeName_7b927cbf-504f-4ed1-b0ee-3b8538a56215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8ccc7e63-2b9f-4ed7-ae38-84fb49822660" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_WrittenCommunications_8ccc7e63-2b9f-4ed7-ae38-84fb49822660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5f3b2eef-f403-4558-9f2a-59a25202989e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_SolicitingMaterial_5f3b2eef-f403-4558-9f2a-59a25202989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_cdffd7a8-9b84-48f4-8329-e6751e93d020" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_PreCommencementTenderOffer_cdffd7a8-9b84-48f4-8329-e6751e93d020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9bd4b73c-6a70-41a2-ba4d-d6203ba8adc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9bd4b73c-6a70-41a2-ba4d-d6203ba8adc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dc0549d6-7171-440c-a3be-235bd6e89ab4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityEmergingGrowthCompany_dc0549d6-7171-440c-a3be-235bd6e89ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bd0736b1-b229-4c51-98a2-614f02339b28" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_AmendmentFlag_bd0736b1-b229-4c51-98a2-614f02339b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4f22a885-611b-4ad1-a55f-771055162b15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17c025ee-6f85-49de-ac95-3185acc91678" xlink:to="loc_dei_EntityCentralIndexKey_4f22a885-611b-4ad1-a55f-771055162b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>nbix-20210108_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20210108.xsd" xlink:type="simple"/>
    <context id="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV80L2ZyYWc6MWNmM2Y4M2U1NDk2NGFkZThhMWY0MTgyNGZlNTUzNWYvdGFibGU6OTAxN2I3YzExZmJiNDZkMDlkYmU0NjlkNTJkZDMzZDYvdGFibGVyYW5nZTo5MDE3YjdjMTFmYmI0NmQwOWRiZTQ2OWQ1MmRkMzNkNl8wLTEtMS0xLTA_9fb942c2-9326-466e-b4d9-2306031e0875">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV80L2ZyYWc6MWNmM2Y4M2U1NDk2NGFkZThhMWY0MTgyNGZlNTUzNWYvdGFibGU6OTAxN2I3YzExZmJiNDZkMDlkYmU0NjlkNTJkZDMzZDYvdGFibGVyYW5nZTo5MDE3YjdjMTFmYmI0NmQwOWRiZTQ2OWQ1MmRkMzNkNl8xLTEtMS0xLTA_ff34529b-a185-400f-b87e-d6d10d7786c0">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYw_94033921-3e0c-4430-a25f-cabf084dc33c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8yMjI_6fd0cc14-be06-49e3-9a4c-7919779a866d">2021-01-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYx_80af7910-82bd-4e29-82a5-59baa262ba44">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN18wLTAtMS0xLTA_6459ebdb-4c25-487d-859e-c1ac9d86fd14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN18wLTEtMS0xLTA_f12442d2-6a8f-4c4d-98ab-9c36089c63fd">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN18wLTItMS0xLTA_c5fabeb5-52c8-46ae-8cc8-b3b22f1e21cb">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN180LTAtMS0xLTA_a4d1ac41-5b87-4569-b24e-658a60935bd7">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN181LTAtMS0xLTA_3956a238-ad0c-4c8f-a7ff-dad9954e4d6d">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN181LTEtMS0xLTA_2d49e314-b275-410b-9356-e47102f28627">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6YTYxYWZlMTc1MmUyNGMyZWFkZDEyY2M5MmIzOGRiZTcvdGFibGVyYW5nZTphNjFhZmUxNzUyZTI0YzJlYWRkMTJjYzkyYjM4ZGJlN181LTItMS0xLTA_2c6949c1-4fe6-4690-bfc9-a5c6e68c756f">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY0_1875815b-a9b4-4ff0-a864-63baba289a97">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYy_140dae5b-d9e9-474a-949c-26e46232c08b">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6NmFjOTc3ZjA4YTc0NDQyYWEwM2JhNTExYjg5NDE0OWUvdGFibGVyYW5nZTo2YWM5NzdmMDhhNzQ0NDJhYTAzYmE1MTFiODk0MTQ5ZV8yLTAtMS0xLTA_7569f06b-ba07-4e60-9d5f-e0738760f31a">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6NmFjOTc3ZjA4YTc0NDQyYWEwM2JhNTExYjg5NDE0OWUvdGFibGVyYW5nZTo2YWM5NzdmMDhhNzQ0NDJhYTAzYmE1MTFiODk0MTQ5ZV8yLTItMS0xLTA_f39fe4ec-240e-49d9-a514-ea902b9af98c">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGFibGU6NmFjOTc3ZjA4YTc0NDQyYWEwM2JhNTExYjg5NDE0OWUvdGFibGVyYW5nZTo2YWM5NzdmMDhhNzQ0NDJhYTAzYmE1MTFiODk0MTQ5ZV8yLTQtMS0xLTA_56735f14-f29a-4866-8177-177b21c0df2c">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY1_ac6ec27a-51bb-478e-91ba-c4b97bfe95c6">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY2_b3ca8f22-6e79-4736-a6ce-b98d1df7dae8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTYz_6c6b8dde-5077-47cb-8005-7161a23be514">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY3_3d3eb375-7c54-4324-b76f-80f65f2240ce">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmMjRmZmMzY2MyMjRjYjNiOTliMzU0M2YzZjU5NDA1L3NlYzowZjI0ZmZjM2NjMjI0Y2IzYjk5YjM1NDNmM2Y1OTQwNV8xL2ZyYWc6OGRkZTM1NTQ0ZDRmNDY5N2FjMTdkOTU1YzBiYjdjMjgvdGV4dHJlZ2lvbjo4ZGRlMzU1NDRkNGY0Njk3YWMxN2Q5NTVjMGJiN2MyOF8xNTY4_cb272ef5-4d86-4f3a-9717-5be75e86c199">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139702747092840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  08,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  (/"A2C ;# # $   O$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)68T7+B-A2&K[=/H6%ZT<Y ;!D(9(<P0QRRI;M+:)SM=MKIA; %:&)+KBP'
M\O8],F#3J3DF7&#)UOGY=([]RV*T5?HEVW!NR"Z)97;;VAB3?G2<+-SPA&57
M*N42KJR43IB!KEX[6:HYBXJ@)'8\U[UV$B9D:SPJSBWT>*1R$PO)%YID>9(P
M_7;'8[6];='6\<236&^,/>&,1RE;\X";;^E"0\\I52*1<)D))8GFJ]O6A'Z\
M\WHVH!CQN^#;[*1-[%262KW8SBRZ;;F6B,<\-%:"P>&5^SR.K1)P_',0;96_
M:0-/VT?UAV+R,)DER[BOXN\B,IO;UK!%(KYB>6R>U/87?IA0W^J%*LZ*;[+=
MC^WU6B3,,Z.20S 0)$+NCVQW2,1)0)>>"? . 5[!O?^A@O*>&38>:;4EVHX&
M-=LHIEI$ YR0MBJ!T7!50)P9^^J5ZY%C0,J><,)#V-T^S#L3]BN35\0=MHGG
M>O2_X0X0E!A>B>$5>ET,@_PU669&0Z'^1B2[I62WD.R=D;Q780ZWCR'/;RFO
MFR$>/NQ\1B!Z)43O,H@%UT)%9"HC G6JY<&5BHP/VS]\^-"0\GZ)UD<%I]((
M\T:>^%K8I /CG"6U8+C.?/KMZ=%_FLVGY&[V&/BSZ=R?!FTRF_M7".9UB7E]
M">9,ADJG2C/[++=)8"")1&GBJUP:_0;'J)8=%[^?(H2#DG!P">&#B#F9Y\FR
M_GG"-=R.YPW</D(S+&F&E] \LQV917#GB94(BZ0A;+ABM]MQ^UZ?]C"\FQ+O
MYA*\211IGF7M8X-\@7'D4=;6$%>DWF#HDFE,? ;^J."&9G$;(:5N98WNNUA]
MVX-[[EEM9:UEXG(!D^1>\+5"Z4Z,F[Z+KGPD%EJ]"AG6IK)!TY]@:)694^]=
M: N5&1:3/T5Z]CEM4+SQ:-?%V*I5@>*^7A1Q B\PYU$:%H;^$ .I5@:*&_H7
M%4).%ALE,=MH$+FF@\[@VD534RT(%'?R9V' PM2*4.^GY<\DX&&N(5NU6+B2
MKY($'"<P*GQIDQ_=*]>E)&6:O+(XYQALM2Q0W+J?-8N$7)/@+5FJN)81%YC?
MS?[ 2"K[I[AW'_-$IKMPP^2:GUU(&X3FD^!^\AO&5"T"%/?L[P!DN"2V$+D\
MK !9+1,NM&)QAA:L,GZ*^W2@8A$*8VOV%9Q*"U9?-5REB<>KW-W#[7BA>2>$
M]'"PROU[(I<1O(0^KE;UCV*#7B-9Y>P>[L+_(YME60YDC8"X;"/@R<OZ1?X^
M3;A>VWI^ @6SL3=;RF2M7S0(-J)5]N[A[CR!A$5%TAYBMJY%P04:42J#]W!O
M/F3)!Q@-3C^#XNW(9UZ?'US*A<\-[?4&M:]@SLGVSVZEOS);EHS$? 5J[M4
MS%KO=Z?[CE%IL2-<*@/[RZ*Y@1T]UW8 7%\I98X=N\DL_R,8_PM02P,$%
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ "#PH4JK$(A8S 0  (@(   \
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M4$L! A0#%     @ "#PH4C<#<IGO    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "#PH4IE<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  (/"A2C ;# # $   O$   &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "#PH4H.II0/4 0  ,@8
M  T              ( != P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  (
M/"A2EXJ[',     3 @  "P              @ %S#@  7W)E;',O+G)E;'-0
M2P$"% ,4    "  (/"A2JL0B%C,!   B @  #P              @ %<#P
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "#PH4B0>FZ*M    ^ $  !H
M             ( !O!   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "#PH4F60>9(9 0  SP,  !,              ( !H1$  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ZQ(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20210108.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-20210108.htm">nbix-20210108.htm</File>
    <File>nbix-20210108.xsd</File>
    <File>nbix-20210108_cal.xml</File>
    <File>nbix-20210108_def.xml</File>
    <File>nbix-20210108_lab.xml</File>
    <File>nbix-20210108_pre.xml</File>
    <File>nbix-20210108exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20210108.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20210108_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20210108_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20210108.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20210108_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20210108_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20210108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20210108",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210108.htm",
      "contextRef": "ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.neurocrine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20210108.htm",
      "contextRef": "ifc5085b2ed3941eba075ab4b0a07810b_D20210108-20210108",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000914475-21-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-21-000004-xbrl.zip
M4$L#!!0    (  @\*%)G?1) H14  ,F$   1    ;F)I>"TR,#(Q,#$P."YH
M=&WM76ESVDBW_CZ_HB]S[[Q.E1NT+SCQ6P[&'C(!$HS' U]<+77+"(3$2,*
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M('R;W8-3(9<I5Y%+DI95B)-$P3A]6.6I@R2_]C1+<W&:92]>+@?>0+02,S+
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M(P65C(-+1>59P7[@3QU$M)8L:S1<"5E=0D&:4L^=AG]O2,D*!KE)>@DVK2/
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M#M)ZXY"^_FSUQH?K]OO) =P9MF?[8O(34$L#!!0    (  @\*%*C!G+@@P$
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MH[]0(_X&3F49??JQN^,M]B4(:6PIN1,P(C>S<Z=X:>>=_[<O\D_"67#!P+F
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M*A]RF0BYJI:UT$XLWDSTJYF0\6PSZEWIBV92!D@$W 6^XA'P_8#J(<O# *F
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M!FWH5;V]T*_.7FS>B5=?ZGWVXG]02P,$%     @ "#PH4O.V>ABJ!@  :C$
M !4   !N8FEX+3(P,C$P,3 X7W!R92YX;6S5FEM3V\@2Q]_Y%#[>US-X[A<J
ML,5ADU/483=4PE:VSHMK+CV@BBU18Q'@VY^6@-T0R%D55A6*'WR11^J>?__<
MZFG/FY]OUJO9%RB;JJGWYVR7SF=0QR95]?G^_/>S=\3.?S[8V7GS#T+^^->'
MD]DO3;Q:0]W.C@KX%M+LNFHO9I\2;#[/<FG6LT]-^5Q]\80<]"<=-9>WI3J_
M:&><<O;MMV5/"A-T]I0 MXE(P30)5C'"G-969.]REO\\WP/-9=!*$&Z#(I*!
M(4%&37B$P*7&2QO77W15U9_WNJ?@-S##R=6;_N/^_*)M+_<6B^OKZ]V;4%:[
M33E?<$K%XF'T_'[XS9/QUZ(?S9QSB_[;/X=NJN<&XF79XH]?3S[&"UA[4M6;
MUM>Q,["I]C;]P9,F^K;7_&_]FGUW1/>)/ PCW2'".!%L]V:3Y@<[L]F='*59
MP0?(L^[U]P_'CTS6<%6:6*H:=F.S7G1#%D<- H'.]B>WMY>P/]]4Z\L5/!R[
M*)#WYW6H;D@75<JH[4S^='?BXB_+EP4V"$L_TQ,\<']^9^4E7L!-"W6"N[D]
MV%@U\=&@5:=L\^>9*Q]@U1]=)JB6_54/PZ8M/K9+9B+E"H#H;!$KEX#XZ!1*
M:)6/T3%M[.-)=TYOT.L^$!N(N^?-EP5>& /":?>F4X02RN[#\-,3HW?ZO,S[
MAU_?&8Y=<NW!*N<PYL"(!'#$"OP92,,L2X+K0-4(SG]M\['O7T?WL,194Q(4
M3"(/1GV)3R+]&.#[$8M+7_!")%Y4J_1P=I=-QHA;VXR@WUUPT-WY#&>=H11(
M)W>Q^>[D^IFUF%JA'SE&W$^A5$UZ6Z=?,/<NK9$0 F#:Y%U2Y$(3%U,F-"4N
M3 :7F!\1@$?&!Y' IT_"RQ5]923>UFW5WGZ \ZI3HFY_\VM$VFBA4D[$IDB)
M#,(3EUPF0H&10B1J$QN!B.=L#P)"3!>(K?6<! _'6+N5RZ;TPG]$_>&HN:K;
M<GO4)%AF;:1S%JNK' .1WC-BK46!N&+,9&8TRZ/A\7]=&42+G#HMXZD]"7C>
M52OX[6H=H"PQVZ7$6"0R<KPC)BS+'>"3EXD'  DQRM%(^<ON("S4U+%XH8Z3
M8.#,WQPGU*K*U=T"Y7XB3"M,?-R0F!3>'@-.R3$J"<]:44IY3'X\(+[CQ" Z
M]-3I&$/A2:!RF!*&8'/_@LL[8$OPCHH0.,DI"B)M,,3KKI[264;GG<#':)@\
MX\ @1,S4$=E6V2GA<81OWY>SYKI>"NICIBJ3%/!>*#FR;AD%8JQ*E&?OLQZO
M_'AB?A :]@=!XX6J3@F,OEYZ7TY+\Z6J(RRII(HR9!MR=[_T&8B5)A+CF*0R
MAI SC$W'-SX,0L3]((ALH^^4.#EM-JU?_;>ZO"NJ378FATR\TQQIUT!<3I)(
MXX)7+D5(X]4ASWDPK 5&?Q!(7B[N*R/2)<## K[W6^2<$\=E>@B ?LO,B$_.
M$\.I,48:X?085<?7-H=A,.%6Z(L%?.7 =W^<K$XOFOIAB>693A9PQE9+P+S&
M# D@.8E29,J8#Y2&$8+_K=UA $RX [J5D*\,P4>(5P4!9CR<5>T*EM%+*WD*
MQ&F+ &?ML3K6CJ08O-1&@U%\! B^M3L,@@EW/;<2\I4A."N^^YOZX^TZ-*NE
MCTK)G"4)%#S>L< 2+S0CS JJ-169JS0" 8^,#@O_A-N8+Y=P(@G@[4V\\/4Y
M]-UZ$QPW$<L7164F$A+K9@)$!*N$]4IS-L8?HL_9'D;"A#N76POZRD!\0N=;
MJ(^:]?JJOF^L;98VQFA "\*#ZR=@B =A<>&3@W26<\1Z!"*>-3X,B0FW*[>7
M]+631+.J8M5B@OL5E\*E\JNERB)P@$RRI()(I2RN<+@GRGFN,++.NC&:#$\M
M#Z-APIW)+<5\911."W0<0QVAW__1;2,J[S/ZL8P)US[&H^_!XE+7XOW/"NX(
M:*,8.)$PO",@\7T/AJ$QX<[D2.)."Y'CS>8*RM=S<2')8$0DVAM*)/.<8$V<
M2-*<BN"M3W&,\N+O_!B&RX2[E*,*/8E.Y=LUE'/,C/\NS75[@9.[]/7M,D6J
M4!5-##.,2$DCEM,!"!<J) W6^3!>J_)9%X9MTII\KW)[>5^9DD/D/'6LOUOY
M\V5(U @=L);FW9Z J!AQ%AG73&;*A7"!C['I])'1821,N%WY<@DGD2&.T//B
M5\>8Y&[^ [=+F3GW%A70C'5[@W!EY97*Q!A&E6*:AU&6JL\:'\;"A#N7VTLZ
M&A-O%D]$/,$#!SOW7W1/W>;\@YW_ 5!+ P04    "  (/"A2"2M2+4 9  #@
MF0  &P   &YB:7@M,C R,3 Q,#AE>&AI8FET.3DQ+FAT;>T]:7,;-[+?WZ_
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M#@JE"ND -H2_)?G[0)O%N_>0]FL"NR^!O1!XN+@9CMTP08<;W,X$:.W7JR*
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MFC]$N=^"-MO"#%/X;^@2]>0_4$L! A0#%     @ "#PH4F=]$D"A%0  R80
M !$              ( !     &YB:7@M,C R,3 Q,#@N:'1M4$L! A0#%
M  @ "#PH4E!2I6N( @  ?0D  !$              ( !T!4  &YB:7@M,C R
M,3 Q,#@N>'-D4$L! A0#%     @ "#PH4J,&<N"# 0  R@(  !4
M     ( !AQ@  &YB:7@M,C R,3 Q,#A?8V%L+GAM;%!+ 0(4 Q0    (  @\
M*%*K%Z,?!P(  &\&   5              "  3T:  !N8FEX+3(P,C$P,3 X
M7V1E9BYX;6Q02P$"% ,4    "  (/"A2D6,?9T,*  "B70  %0
M    @ %W'   ;F)I>"TR,#(Q,#$P.%]L86(N>&UL4$L! A0#%     @ "#PH
M4O.V>ABJ!@  :C$  !4              ( ![28  &YB:7@M,C R,3 Q,#A?
M<')E+GAM;%!+ 0(4 Q0    (  @\*%()*U(M0!D  ."9   ;
M  "  <HM  !N8FEX+3(P,C$P,3 X97AH:6)I=#DY,2YH=&U02P4&      <
,!P#3 0  0T<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
